Dr David Sugarbaker - Revision history

MesotheliomaSupport: Redirect: consolidate duplicate (period variant)

2026-04-23T13:47:22Z

Redirect: consolidate duplicate (period variant)

← Older revision		Revision as of 13:47, 23 April 2026
Line 1:		Line 1:
	#REDIRECT [[Dr.~~_David_Sugarbaker~~]]		#REDIRECT [[Dr. David Sugarbaker]]

MesotheliomaSupport: Consolidate duplicate URLs: redirect to canonical Dr._David_Sugarbaker

2026-04-23T13:38:18Z

Consolidate duplicate URLs: redirect to canonical Dr._David_Sugarbaker

Show changes

MesotheliomaSupport: Fix MediaWiki cite errors: remove unused ref definitions / move references block to end

2026-04-22T16:36:19Z

Fix MediaWiki cite errors: remove unused ref definitions / move references block to end

Show changes

MesotheliomaSupport: Converting duplicate page to redirect for SEO cleanup

2026-02-12T01:08:56Z

Converting duplicate page to redirect for SEO cleanup

Show changes

MesotheliomaSupport: Add authoritative external references (PubMed, Brigham IMP), fix dark mode, convert to proper ref format

2026-02-11T02:46:36Z

Add authoritative external references (PubMed, Brigham IMP), fix dark mode, convert to proper ref format

Show changes

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:28:55Z

Fix dark mode compatibility: remove problematic background/text colors

MesotheliomaSupport: Bot edit

2026-01-29T00:05:09Z

Bot edit

Show changes

MesotheliomaSupport: Bot edit

2026-01-28T23:54:28Z

Bot edit

Show changes

MesotheliomaSupport: Bot edit

2026-01-28T23:42:25Z

Bot edit

Show changes

MesotheliomaSupport: Expand Executive Summary to fix layout

2026-01-28T22:02:17Z

Expand Executive Summary to fix layout

← Older revision		Revision as of 22:02, 28 January 2026
Line 37:		Line 37:

	Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma: Diagnosis, Treatment & Legal Help], Mesothelioma Lawyer Center</ref>		Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure, modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> His research demonstrated that this aggressive approach could extend median survival to 35.6 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref> In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he had performed more mesothelioma surgeries than any other surgeon in history.<ref>[https://www.mesotheliomalawyercenter.org/entity/mesothelioma/ Mesothelioma: Diagnosis, Treatment & Legal Help], Mesothelioma Lawyer Center</ref>

			The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System, and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, clinical trials, and training programs that advanced the field worldwide.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>

			Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.<ref>[https://mesothelioma.net/mesothelioma-surgery/ Mesothelioma Surgery], Mesothelioma.net</ref>

	== Key Facts ==		== Key Facts ==

← Older revision		Revision as of 14:28, 29 January 2026
Line 7:		Line 7:
	\|published_time=2026-01-28		\|published_time=2026-01-28
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276~~; background:#ffffff~~; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. David J. Sugarbaker, MD		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Dr. David J. Sugarbaker, MD
	\|-		\|-
	\| colspan="2" style="~~background:#e8f4f8;~~ padding:10px; text-align:center; font-style:italic;" \| Architect of Trimodal Therapy		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| Architect of Trimodal Therapy
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%~~; background:#f8f9fa~~; border-bottom:1px solid #dee2e6;" \| Born		\| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" \| Born
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 6, 1949		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 6, 1949
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa~~; border-bottom:1px solid #dee2e6;" \| Died		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Died
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 29, 2018 (age 69)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| August 29, 2018 (age 69)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa~~; border-bottom:1px solid #dee2e6;" \| Institution		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Institution
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Brigham and Women's Hospital		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Brigham and Women's Hospital
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa~~; border-bottom:1px solid #dee2e6;" \| Key Innovation		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Key Innovation
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Trimodal Therapy		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| Trimodal Therapy
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa~~; border-bottom:1px solid #dee2e6;" \| Program Founded		\| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" \| Program Founded
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International Mesothelioma Program (2002)		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| International Mesothelioma Program (2002)
	\|-		\|-
	\| style="padding:10px; font-weight:bold~~; background:#f8f9fa~~;" \| Survival Achievement		\| style="padding:10px; font-weight:bold; " \| Survival Achievement
	\| style="padding:10px;" \| 35.6 months median		\| style="padding:10px;" \| 35.6 months median
	\|-		\|-
Line 48:		Line 48:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. David Sugarbaker's Contributions		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Dr. David Sugarbaker's Contributions
	\|-		\|-
	\| style="padding:15px~~; background:#f8f9fa~~;" \|		\| style="padding:15px; " \|
	* '''Surgical Innovation:''' Pioneered extrapleural pneumonectomy (EPP) for mesothelioma		* '''Surgical Innovation:''' Pioneered extrapleural pneumonectomy (EPP) for mesothelioma
	* '''Trimodal Therapy:''' Developed approach combining surgery + chemotherapy + radiation		* '''Trimodal Therapy:''' Developed approach combining surgery + chemotherapy + radiation
Line 67:		Line 67:
	His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.<ref>[https://mesothelioma.net/multimodal-therapy/ Multimodal Therapy for Mesothelioma], Mesothelioma.net</ref>		His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.<ref>[https://mesothelioma.net/multimodal-therapy/ Multimodal Therapy for Mesothelioma], Mesothelioma.net</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered."
Line 106:		Line 106:
	\|}		\|}

	{\| style="width:100%~~; background:#fff3cd~~; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#856404~~;" \| '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.		\| style="padding:15px; " \| '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery.
	\|}		\|}

Line 142:		Line 142:
	In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.6 months, with half of patients living even longer.<ref>[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer], Mesothelioma Lawyer Center</ref>		In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.6 months, with half of patients living even longer.<ref>[https://www.mesotheliomalawyercenter.org/asbestos/cancer/ Asbestos Cancer], Mesothelioma Lawyer Center</ref>

	{\| style="width:100%~~; background:#d4edda~~; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px~~; color:#155724~~;" \| '''✅ Survival Achievement:''' Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.6 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.		\| style="padding:15px; " \| '''✅ Survival Achievement:''' Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.6 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment.
	\|}		\|}

Line 163:		Line 163:
	This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>		This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.<ref>[https://mesothelioma.net/mesothelioma-treatment-centers/ Mesothelioma Treatment Centers], Mesothelioma.net</ref>

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease."
Line 239:		Line 239:
	* '''Research Infrastructure:''' Tissue banks and databases support ongoing research		* '''Research Infrastructure:''' Tissue banks and databases support ongoing research

	{\| style="width:95%; margin:1em auto~~; background:#f8f9fa~~; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families."